SUE ANN RANKIN NP
Prescription History 1891950721
Nurse Practitioner in Amarillo, TX


Quality Rating: 100 out of 100 score

NPI Status: Active since July 21, 2008

Contact Information

1400 S COULTER ST
AMARILLO, TX
ZIP 79106
Phone: (806) 414-9800
Fax: (806) 354-5689

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SUE ANN RANKIN NP, an active Nurse Practitioner specialist practicing in Amarillo, TX. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Tresiba Flextouch U-200, which accounts for 11 claims alone.

Medication Index

No matching medications currently found on file.

Tresiba Flextouch U-200

Generic Formulation: Insulin DegludecSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 117
TX State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills61.2
Peer Average Days Supply1,787
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,250.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$659.17

State Avg Cost Per Claim

$1,231.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SUE ANN RANKIN NP provides transparency into local medical care patterns within Amarillo, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.